- Home
- SF vs QGEN Comparison
SF vs QGEN Comparison
Compare SF & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SF | QGEN |
|---|---|---|
| Founded | 1890 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 10.2B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | SF | QGEN |
|---|---|---|
| Price | $70.72 | $39.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $89.17 | $51.30 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | 1.93% | ★ 5.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.04 | $8.18 |
| Revenue Next Year | $7.61 | $5.66 |
| P/E Ratio | ★ $20.53 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.31 | $38.13 |
| 52 Week High | $134.74 | $57.82 |
Technical Indicators
Market Signals| Indicator | SF | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 20.67 | 23.55 |
| Support Level | N/A | N/A |
| Resistance Level | $116.74 | $49.11 |
| Average True Range (ATR) | 1.89 | 0.97 |
| MACD | 0.74 | -0.36 |
| Stochastic Oscillator | 20.20 | 1.81 |
Price Performance
Historical ComparisonAbout SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).